VIP, a 28-amino acid residue neuropeptide, widely distributes in the central and peripheral nervous system. 7) This peptide has a vasodilating effect, and is an important neurotransmitter for the enteric nervous system. [8] [9] [10] Gastrin, a 17-amino acid residue polypeptide, stimulates gastric acid secretion. This peptide is associated with a mechanism of gastrointestinal motility involving the cholinergic nervous system. 11) Somatostatin, a 14-amino acid residue polypeptide, inhibits the secretion of other polypeptides, including gastrin, insulin, and motilin. 12) In the gastrointestinal tract, gastric acid and pepsin secretion and gastric emptying are inhibited by somatostatin. 13, 14) The purpose of this study was to determine the effects of Ninjin-to on the plasma levels of motilin-, VIP-, gastrin-, and somatostatin-immunoreactive substance (IS) in healthy subjects.
MATERIALS AND METHODS
Materials Ninjin-to (EK-32, lot. 01BJ), prepared as a 3.0 g dried powder extract in the following proportions: Ginseng Radix (3.0 g), Glycyrrhizae Radix (3.0 g), Atractylodis Rhizoma (3.0 g), and Zingiberis Siccatum Rhizoma (3.0 g), was kindly supplied by Kanebo Co., Ltd. (Tokyo, Japan). A mixture of sucrose and cellulose, consisting of EK-32 as additive, was used as a placebo. All other reagents were reagent grade and commercially available. Synthetic porcine motilin, that has a sequence identical to human motilin, synthetic vasoactive intestinal peptide (VIP), synthetic human gastrin I (G17), and synthetic somatostatin were purchased from Peptide Institute Inc. (Osaka, Japan). Antisera to motilin (A602/R1B), VIP (A604/R1B), and gastrin (A600/R1B) were purchased from Biogenesis, Ltd. (U.K.). An antiserum to somatostatin was purchased from Cambridge Res. Subject Five healthy male volunteers (non-smokers) participated in this study. Each subject received information about the study's scientific purpose, which was approved by the Ethics Committee at Oita Medical University, and gave informed consent. No subject received any medication for two weeks preceding the test and no stimulator of gastrointestinal motility, except Ninjin-to, was administered to any subject during the study.
Study Schedule Ninjin-to and placebo were packaged identically. Ninjin-to was given orally as a single dose of 6.0 g with water to the 5 volunteers. Two weeks later, the same dose of a placebo was given orally to the volunteers. Venous blood samples (10 ml) from a forearm vein were taken to measure the levels of each peptide in plasma by enzyme immunoassay (EIA). Samples were taken before and at 20, 40, 60, 90, 120, 180, and 240 min after administration of the drug. All subjects ate lunch at 11:45-12:00 and the study was carried out from 14:00 (2 h after lunch) until 18:00.
Preparation of Plasma Extracts
The blood samples were placed in chilled tubes containing 500 kallikrein inhibitor units/ml of aprotinin (Trasylol ® , Bayer Co., Ltd., Leverkusen, Germany) and 1.2 mg/ml of EDTA (Wako Pure Chemical Industries, Ltd., Osaka, Japan). After centrifugation (1670ϫg, 4°C, 20 min), plasma samples were diluted with 4 ml of 4% acetic acid, pH 4.0, and loaded onto SepPak ® C18 cartridges (Millipore Co., Massachusetts, U.S.A.). After washing with 4% acetic acid, pH 4.0, each peptide in plasma was eluted with 70% acetonitrile in 0.5% acetic acid, pH 4.0. The eluates were concentrated by spin-vacuum evaporation, lyophilized, and stored (Ϫ40°C) until high sensitive enzyme immunoassay (EIA). The recovery of plasma motilin-, VIP-, gastrin-, and somatostatin-IS was Ͼ93% with this extracting procedure (data not shown).
EIA for Motilin-, VIP-, Gastrin, and Somatostatin-IS Peptide levels in plasma were measured using EIA for motilin-, 15) VIP-, 16) gastrin-, 17) and somatostatin-IS 18) as previously described. The assay was performed by a delayed addition method. Separation of bound and free antigen (peptides) was performed on an anti-rabbit IgG coated immunoplate (Nunc-Immuno Module Maxisorp F8, InterMed, Denmark). Human motilin, fragment of VIP (positions 11-28), mini gastrin I, and human somatostatin were conjugated with b-galactosidase by N-(e-maleimidocaproyloxy)-succinimide according to the methods of Kitagawa et al. 19) Tubes containing antiserum for each peptide and extracted samples (or standard) were incubated at 4°C for 24 h, and then enzymelinked antigen was added. After incubation for another 24 h, each antigen-antibody solution was put in secondary-antibody coated immunoplates and the plates were incubated overnight. Then, after washing with phosphate buffer, MUG was added to each well. The plates were incubated again at 37°C for 3 h and the fluorescence intensity (l Ex 360 nm, l Em 450 nm) of each well was measured with a MTP-100F microplate reader (Corona Electric, Ibaraki, Japan). The detection unit of motilin-, VIP-, gastrin-, and somatostatin-IS was 0.80, 1.00, 0.04, and 0.10 fmol/well, respectively.
Data Analysis All values are expressed as meanϮS.D. Comparisons of mean values were made by analysis of variance and Dunnett's test. A value of pϽ0.05 was regarded as significant.
RESULTS AND DISCUSSION
Ninjin-to has frequently used for thousands of years to improve gastrointestinal functions. In this study, four types of brain-gut peptide (motilin, VIP, gastrin, and somatostatin), which regulates gastrointestinal motility, were examined to study the effects of Ninjin-to.
Motilin is a powerful inducer of gastrointestinal motor activity in the fundus and the antral pouch of the stomach.
4)
The plasma motilin-IS level-time profile after a single oral administration of Ninjin-to or placebo is shown in Fig. 1(A) . Ninjin-to caused significant increases in motilin-IS at 40 min (41.1Ϯ11.7 pg/ml), 60 min (50.5Ϯ11.4 pg/ml), and 90 min (61.1Ϯ12.1 pg/ml) compared with the response of the placebo treated group (about 25 pg/ml), whereas in the placebo group, the basal line of plasma motilin-IS levels might be the effect of circadian rhythms. Accordingly, those changes of motilin-IS levels in the Ninjin-to treated group suggest that this drug might affect motilin-IS levels in human plasma through some pathways.
VIP has a vasodilating effect and functions as a neurotransmitter for the enteric nervous system. 7) Ninjin-to had no effect on plasma VIP-IS levels compared with the placebo treated group (Fig. 1(B) ). Furthermore, plasma VIP-IS levels of both groups remained constant before and after adminis- Gastrin is associated with a gastrointestinal motility involving cholinergic nerves.
11) The plasma gastrin-IS leveltime profile of Ninjin-to or placebo is shown in Fig. 1(C) . Ninjin-to did not significantly alter gastrin-IS levels between 40-240 min compared with the response of the placebo treated group, but a temporary elevation (20 min) in plasma gastrin-IS levels of placebo was significantly inhibited by Ninjin-to administration. The gastrin secretion in placebo might be caused by stimulation of the gastric mucosal G cell.
Somatostatin acts as an inhibitor of hormone release. The plasma somatostatin-IS level-time profile of Ninjin-to or placebo is shown in Fig. 1(D) . Ninjin-to causes significant increase in somatostatin-IS at 20-90 min [20 min (14.4Ϯ2.1 pg/ml), 60 min (16.1Ϯ4.8 pg/ml), and 90 min (15.0Ϯ4.6 pg/ml)] compared with the response of the placebo treated group (about 10 pg/ml). These increases suggest that Ninjinto might inhibit gastrin release through secretion of somatostatin. In general, somatostatin inhibits the secretion of gastrin and gastric acid secretion and motilin. [12] [13] [14] But in our study, Ninjin-to caused significant increases in motilin-IS levels. This implies that the intercellular communication between somatostatin and gastrin is paracrine, while that between somatostatin and motilin is common endocrine.
Ninjin-to is an herbal medicine, prepared from four herbs: Ginseng Radix (GR), Glycyrrhizae Radix, Atractylodis Rhizoma, and Zingiberis Siccatum Rhizoma (ZR). GR and ZR were reported to act to enhance gastrointestinal motility. 20, 21) From the viewpoint of contractions on gastrointestinal tract, GR caused jejunal contraction with elevation of tonus in the rabbit. 22) Somatostatin, a polypeptide, which distributes widely in the gastrointestinal tract, participates in the control of gut motility by exerting both inhibitory and stimulating influences. In other words, in the interdigestive state somatostatin induces phase-3 activities, [23] [24] [25] [26] and in the digestive state it inhibits gastric emptying 27) and slows gastrointestinal transit. 28) Somatostatin is the first of the gut regulatory peptides to have a significant therapeutic use. To date most clinical experience has been with one analogue, octreotide. 29) This analogue has a longer half-life than somatostatin, and stimulated MMC-like activity in the small intestine. 30) In patients with scleroderma the administration of octreotide reduces bacterial overgrowth and improves abdominal symptoms. This peptide pharmaceutical may be useful for treatment of intestinal dysmotility. 31) Some of these effects of peptides might correspond with experiential gastrointestinal actions of Ninjin-to.
Motilin participates in regulating gastrointestinal motility with somatostatin. In this study, motilin-IS levels by Ninjinto administration were enhanced by several pathways. That elevation also seemed to indicate that Ninjin-to might enhance motor activity in a small intestine, including phase-3 contractions of MMC. 5, 6) We hypothesize that Ninjin-to might improve the gastrointestinal functions by increasing motilin-and somatostatin-IS levels in plasma. Although further studies are needed to elucidate the mechanism, our findings indicated the experiential gastrointestinal effects of Ninjin-to are closely related to changes in brain-gut peptide levels in plasma.
